ArticleJournal of clinical medicine2020
Special Issue "Diabetic Nephropathy: Diagnosis, Prevention and Treatment".
Article in Journal of clinical medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 84 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
84 citing papers in PubMed, 5 syntheses or guidelines pooled it, 129 citations in OpenAlex.
- Effects and safety of Salvia miltiorrhiza on the improvement of renal function, inflammatory factors, and vascular endothelium in patients with diabetic kidney disease: a meta-analysis and systematic review.Frontiers in pharmacology · 2025Pooled it
- Efficacy and safety of the traditional Chinese formula Shengjiang powder combined with conventional therapy in the treatment of diabetic kidney disease: a systematic review and meta-analysis.Frontiers in endocrinology · 2024Pooled it
- Comparison of the effects of different percentages of soy protein in the diet on patients with type 2 diabetic nephropathy: systematic reviews and network meta-analysis.Frontiers in nutrition · 2023Pooled it
- Efficacy and safety ofFrontiers in pharmacology · 2022Pooled it
- Traditional Chinese medicine for the treatment of diabetic kidney disease: A study-level pooled analysis of 44 randomized controlled trials.Frontiers in pharmacology · 2022Pooled it
- Randomized controlled clinical trial of Shenzhuo Formula in the treatment of macroalbuminuria in diabetic kidney disease and its inflammation-modulating mechanisms.Precision clinical medicine · 2025Trial
- Efficacy and safety of polyethylene glycol loxenatide in treating mild-to-moderate diabetic kidney disease in type 2 diabetes patients: a randomized, open-label, clinical trial.Frontiers in endocrinology · 2024Trial
- Selective glomerular hypofiltration is associated with glucometabolic disturbances in the general population.Journal of internal medicine · 2026Article
- Multiparametric functional MRI for early detection of renal impairment: clinical applications and future directions.Abdominal radiology (New York) · 2026Review
- Identification and regulatory mechanism analysis of macrophage-related key genes in diabetic nephropathy.Diabetology & metabolic syndrome · 2026Article
- Non-linear associations between red blood cell distribution width/serum albumin ratio with diabetic kidney disease: results from two nationwide studies in the United States and China.Scientific reports · 2026Article
- A non-invasive predictive model for identifying non-diabetic kidney disease in type 2 diabetes mellitus: development and multicenter validation.American journal of clinical and experimental urology · 2026Article
- Development and External Validation of a Clinically Applicable Model for Identifying Diabetic Kidney Disease in Population-Based and Clinical Cohorts.International journal of general medicine · 2026Article
- Nonlinear association between serum insulin, visceral fat area, and kidney function in female with type 2 diabetes: a retrospective study.Frontiers in endocrinology · 2026Article
- New findings in diabetic kidney disease: correlation and enhanced combined diagnostic value of sclerostin and 25(OH)VD.Frontiers in endocrinology · 2026Article
- Identification of key biomarkers of telomere-related genes in diabetic nephropathy via bioinformatic analysis.Frontiers in genetics · 2026Article
- Review
- Cross-country inequalities in the epidemiology of chronic kidney disease due to type 2 diabetes mellitus, 1990-2021: findings from the global burden of disease study 2021.Diabetology & metabolic syndrome · 2025Article
- Association of Left Atrium Remodeling With Major Adverse Cardiovascular Events in Asymptomatic Type 2 Diabetes Patients With Early Chronic Kidney Disease.Reviews in cardiovascular medicine · 2025Article
- The Identification of Biomarkers and Therapeutic Targets for Diabetic Kidney Disease by Integrating the Proteome with the Genome.Biomedicines · 2025Article
24 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetic nephropathy (DN) is the main cause of end-stage renal disease. DN is a complex disease mediated by genetic and environmental factors, and many cellular and molecular mechanisms are involved in renal damage in diabetes. There are no biomarkers that reflect the severity of the underlying renal histopathological changes and can effectively predict the progression of renal damage and stratify the risk of DN among individuals with diabetes mellitus. Current therapeutic strategies are based on the strict control of glucose and blood pressure levels and, although there are new anti-diabetic drugs, these treatments only retard renal damage progression, being necessary novel therapies. In this Special Issue, there are several comprehensive reviews and interesting original papers covering all these topics, which would be of interest to the growing number of readers of the
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.